455 Mission Bay Blvd South
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Our success is rooted in four key elements: our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners, our unique research and development pipeline of new investigational medicines in cancer and immunology, our proprietary and proven science and technology approach that fuels our discovery efforts and our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
462 articles with Nektar Therapeutics
Nektar Therapeutics Reports First Quarter 2020 Financial Results
Cash and investments in marketable securities at March 31, 2020 were approximately $1.5 billion as compared to $1.6 billion at December 31, 2019.
Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of U.S.-based financial markets.
Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference
Nektar Therapeutics' senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time..
Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2019 .
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets
Nektar Therapeutics will announce its financial results for the fourth quarter and year-ended December 31, 2019, on Thursday, February 27, 2020, after the close of U.S.-based financial markets.
Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications
Nektar Therapeutics (NASDAQ: NKTR) today announced the publication of preclinical data on its lead immuno-oncology candidate, NKTR-214, bempegaldesleukin (bempeg) in two manuscripts in Nature Communications.
Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
Nektar Therapeutics issued a statement following a meeting of the Food and Drug Administration's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee to discuss the New Drug Application for oxycodegol where the Committees did not recommend approval of oxycodegol.
In a painful blow to the San Francisco-based company, the committees voted unanimously, 27 to 0, not to recommend approval.
Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)
Nektar Therapeutics (Nasdaq:NKTR) and Bristol-Myers Squibb Company (NYSE:BMY) announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials.
Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
This Webcast will be available for replay until February 21, 2020.
Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.
Dr. Curet brings three decades of experience working in the healthcare sector and academia, and currently serves as Executive Vice President and Chief Medical Officer for Intuitive Surgical, Inc., a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery.
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition for its IL-15 agonist and investigational candidate, NKTR-255.
Nektar Appoints John Northcott as Chief Commercial Officer
John will also serve as a member of the Company's Executive Committee reporting directly to President and CEO, Howard W. Robin.
Top 10 Biotech Bay Companies by Revenue
11/18/2019The companies included on this list are the top ten companies headquartered in Biotech Bay based on 2018 revenue.
Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference
Nektar Therapeutics' senior management is scheduled to present at the upcoming Jefferies 2019 Healthcare Conference in London on Wednesday, November 20, 2019 at 4:00 p.m. Greenwich Mean Time.
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019
Nektar Therapeutics reported its financial results for the third quarter ended September 30, 2019.
Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting
Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company management on Sunday, November 10, 2019 at 9:00 a.m. EST in Washington, D.C. during the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets
Nektar Therapeutics will announce its financial results for the third quarter on Wednesday, November 6, 2019, after the close of U.S.-based financial markets.
Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15 (IL-15) receptor agonist, as monotherapy for patients with relapsed or refractory non-Hodgkin lymphoma (NHL) or multiple myeloma (MM).
Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis
Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients with psoriasis and one in patients with atopic dermatitis.